Kaitlyn Bader, Senior Editor

Renata Block, MMS, PA-C, interviews dermatology clinicians and the Melanoma Research Foundation CEO at the Chicago SPF Fest.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on key career mentors.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on how patient interactions have changed over time.

Michelle Bolas and Rukiyah T. Van Dross-Anderson, PhD, discuss the significance of NCInnovations’ funding and the clinical impact of Van Dross-Anderson's research in patients with advanced melanoma.

This week’s collection of the latest dermatologic studies includes drug-induced epidermal necrolysis in pediatric patients, predicting relapse in chronic spontaneous urticaria, fatigue in patients with psoriasis and psoriatic arthritis, and the role of eosinophils in hidradenitis suppurativa.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on advancements in their careers.

Learn more about the latest research in atopic dermatitis from Raj Chovatiya, MD, PhD, MSCI; Robert Sidbury, MD; David Rosmarin, MD; Amy Paller, MD; Melinda Gooderham, MD, MSc, FRCPC; and Jonathan Silverberg, MD, PhD, MPH.

The international study represents the most comprehensive analysis of Southeast Asian patients with CI to date and provides a detailed look into specific CI subtypes.

Cutiss plans to have full phase 2 data in early 2025.

Patrick Burnett, MD, PhD, provides insights into the significance of Arcutis’ roflumilast cream 0.15% formulation and its impact on pediatric patients.

Christopher Bunick, MD, PhD, provides insights into new research exploring bimekizumab’s unique binding to IL-17F and IL-17A by analyzing crystals of bimekizumab fragment antigen-binding.

The planned PDUFA data was July 7, 2024.

Explore dermatology's history and the journey through our publication's 45 years of covering an ever evolving specialty.

Some patients may be looking for alternatives to BPO, questioning its safety.

Walter Liszewski, MD, shares insights into discrepancies between permanent makeup and decorative tattoos and which patients may benefit from permanent makeup.

In case you missed it, this week we had news about sarecycline's efficacy in periorificial dermatitis, Health Canada's authorization of lebrikizumab for AD, the FDA's investigational new drug clearance of ENS-002 for AD, and more.

Learn more about the in-depth topics covered in the June 2024 print issue of Dermatology Times.

Peter Prieto, MD, MPH, shares details of the IOV-COM-202 trial.

Maryanne Makredes Senna, MD, shares insights into the complexities of treating alopecia areata and guidance for clinicians.

In today’s podcast, Silverberg discusses topical therapeutics for vitiligo and clinical excellence.

A retrospective review found that sarecycline, a narrow-spectrum tetracycline, may be beneficial for patients with POD.

In case you missed it, this week we had news about the FDA approval of sofpironium gel for primary axillary hyperhidrosis, Sun Pharma's "I LUV YA for the Long Haul" psoriasis campaign, the role of laser treatments in preventing cancer, and more.

The post-hoc analysis evaluated the relationship between lebrikizumab serum concentration levels and sustained clinical response after lebrikizumab discontinuation.

The recent news of counterfeit Botox resulted in patients with blurred vision, difficulty swallowing, shortness of breath, and additional symptoms.

Eli Lilly recently hosted a panel discussion with Olympic athlete Suni Lee to discuss the importance of finding a dermatologist who understands the burden of AD.

Omar Noor, MD, and a patient with psoriasis share their unique perspectives on moderate to severe plaque psoriasis treatment with tildrakizumab.

In case you missed it, this week had news about the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference, the FDA-approved expanded use of tirbanibulin for actinic keratosis, FDA and EMA support of continuing MoonLake's phase 3 trial of sonelokimab for PsA, and more.

Catch up on all clinical pearls from the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

Jonathan Silverberg, MD, PhD, MPH, and Melinda Gooderham, MSc, MD, FRCPC, debated which patients are a contender for systemic therapy.

Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.